title: [A female chronic myeloid leukemia patient who gave birth after stopping imatinib intentionally but who maintained a major molecular response with interferon].
abstract: Imatinib was administrated to a 38-year-old woman with chronic myeloid leukemia(CML). A major molecular response (MMR)(≤5 copies/0.5 μgRNA in Amp-CML detected using the transcription mediated amplification/hybridization protection assay(TMA/HPA)method)was achieved in 18 months. She maintained MMR for 10 months, and wished to become pregnant. Imatinib was stopped intentionally because she wished to plan a pregnancy, but we prescribed interferon alpha (IFN-a)due to the likelihood of the CML recurring after pregnancy. The nausea caused by IFN-a was improved by administrating it during the night, and she gave birth to a healthy baby by a normal delivery, whilst maintaining MMR. In this case, IFN-a treatment gave good clinical results, the patient's prognosis was improved, and she could maintain a good quality of life. We consider this to be an informative example of IFN-a therapy for CML during pregnancy.
authors.affiliation: Dept. of Pharmacy, Gifu Municipal Hospital.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Osawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yasuda
authors.forename: Michi
authors.initials: M
authors.lastname: Umeda
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Nagaya
authors.forename: Tomoya
authors.initials: T
authors.lastname: Tachi
authors.forename: Hideko
authors.initials: H
authors.lastname: Goto
authors.forename: Senji
authors.initials: S
authors.lastname: Kasahara
authors.forename: Hitomi
authors.initials: H
authors.lastname: Teramachi
authors.forename: Chitoshi
authors.initials: C
authors.lastname: Goto
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011743:Pyrimidines / Q000627:therapeutic use*; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate